IRD
Opus Genetics
Halal Rating :
Last Price
$1.12
Last updated:
Market Cap
$32.49m
7D Change
-7.44%
1 Year Change
-59.27%
Company Overview
Industries
Exchange
NASDAQ
Next Earnings Date
Nov. 11, 2024
Opus Genetics is a biotechnology company focused on developing genetic medicines for rare inherited retinal diseases. The company leverages its AAV-based gene therapy platform to develop treatments for conditions that cause childhood blindness. Opus is currently advancing several preclinical programs targeting specific genetic mutations that cause inherited retinal diseases.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $3.87m | $11.88m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $1.11m | $9.44m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $1.71m | $9.42m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Opus Genetics's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.